Alcon (ALC) Reports Q4 Earnings: What Key Metrics Have to Say

28.02.24 01:00 Uhr

Werte in diesem Artikel
Aktien

86,36 CHF 0,26 CHF 0,30%

Indizes

1.187,5 PKT 0,7 PKT 0,05%

2.975,3 PKT 0,8 PKT 0,03%

2.143,9 PKT 0,6 PKT 0,03%

7.116,9 PKT -121,9 PKT -1,68%

1.869,0 PKT 4,2 PKT 0,22%

11.390,2 PKT 10,6 PKT 0,09%

1.571,0 PKT 2,5 PKT 0,16%

15.081,7 PKT 30,4 PKT 0,20%

3.368,2 PKT 8,5 PKT 0,25%

4.387,0 PKT 1,7 PKT 0,04%

14.954,8 PKT 30,0 PKT 0,20%

6.660,1 PKT 48,2 PKT 0,73%

For the quarter ended December 2023, Alcon (ALC) reported revenue of $2.33 billion, up 8.2% over the same period last year. EPS came in at $0.70, compared to $0.42 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $2.34 billion, representing a surprise of -0.22%. The company delivered an EPS surprise of +2.94%, with the consensus EPS estimate being $0.68.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Alcon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net sales by region- United States: $1.07 billion versus the two-analyst average estimate of $1.02 billion. Net sales by region- International: $1.27 billion versus the two-analyst average estimate of $1.31 billion. Net Sales- Total Surgical- Equipment/other: $226 million versus the five-analyst average estimate of $214.66 million. The reported number represents a year-over-year change of +10.8%. Net Sales- Total Vision care: $980 million compared to the $982.85 million average estimate based on five analysts. The reported number represents a change of +11.2% year over year. Net Sales- Total Surgical- Consumables: $688 million versus $680.04 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +8.2% change. Revenues- Other revenues: $20 million versus the five-analyst average estimate of $23.26 million. Net Sales- Total Vision Care- Contact lenses: $579 million versus the five-analyst average estimate of $585.55 million. The reported number represents a year-over-year change of +9.3%. Net Sales- Total Vision Care- Ocular health: $401 million compared to the $397.30 million average estimate based on five analysts. The reported number represents a change of +14.3% year over year. Net Sales- Total Surgical- Implantables: $438 million versus $459.04 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +0.9% change. Net Sales- Total Surgical: $1.35 billion versus the four-analyst average estimate of $1.35 billion. The reported number represents a year-over-year change of +6.1%. View all Key Company Metrics for Alcon here>>>Shares of Alcon have returned +5.9% over the past month versus the Zacks S&P 500 composite's +3.8% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Just Released: Zacks Top 10 Stocks for 2024Hurry – you can still get in early on our 10 top tickers for 2024. Hand-picked by Zacks Director of Research, Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2024. You can still be among the first to see these just-released stocks with enormous potential.See New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alcon (ALC): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Novartis

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Novartis

NameHebelKOEmittent
NameHebelKOEmittent
Werbung

Quelle: Zacks

Nachrichten zu Novartis AG

Analysen zu Novartis AG

DatumRatingAnalyst
10.04.2024Novartis BuyUBS AG
04.04.2024Novartis BuyJefferies & Company Inc.
04.04.2024Novartis BuyUBS AG
03.04.2024Novartis NeutralJP Morgan Chase & Co.
28.03.2024Novartis UnderweightBarclays Capital
DatumRatingAnalyst
10.04.2024Novartis BuyUBS AG
04.04.2024Novartis BuyJefferies & Company Inc.
04.04.2024Novartis BuyUBS AG
22.03.2024Novartis BuyDeutsche Bank AG
07.02.2024Novartis BuyDeutsche Bank AG
DatumRatingAnalyst
03.04.2024Novartis NeutralJP Morgan Chase & Co.
25.03.2024Novartis HoldJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
07.02.2024Novartis NeutralJP Morgan Chase & Co.
09.01.2024Novartis NeutralJP Morgan Chase & Co.
08.01.2024Novartis NeutralJP Morgan Chase & Co.
DatumRatingAnalyst
28.03.2024Novartis UnderweightBarclays Capital
06.02.2024Novartis UnderweightBarclays Capital
21.12.2023Novartis UnderweightBarclays Capital
29.11.2023Novartis UnderweightBarclays Capital
23.10.2023Novartis UnderweightBarclays Capital

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Novartis AG nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"